scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1042755389 |
P356 | DOI | 10.1186/S12872-015-0153-7 |
P932 | PMC publication ID | 4668670 |
P698 | PubMed publication ID | 26631004 |
P5875 | ResearchGate publication ID | 285640229 |
P50 | author | Harry P. Selker | Q60057895 |
Gordon S. Huggins | Q114427846 | ||
Joni R. Beshansky | Q124810388 | ||
P2093 | author name string | Robin Ruthazer | |
Inga Peter | |||
Hadeel Alkofide | |||
Jayanta T Mukherjee | |||
Madhab Ray | |||
P2860 | cites work | C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? | Q33678964 |
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. | Q33898507 | ||
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial | Q34204296 | ||
Role of metabolically active drugs in the management of ischemic heart disease | Q35631392 | ||
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment | Q35745797 | ||
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
The principles of metabolic therapy for heart disease | Q36340878 | ||
Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation | Q36402102 | ||
The clinical application of metabolic therapy for cardiovascular disease | Q36873628 | ||
Insulin resistance and inflammation markers in myocardial infarction | Q36975794 | ||
Glucose-insulin-potassium revived: current status in acute coronary syndromes and the energy-depleted heart | Q38086415 | ||
Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon | Q40320383 | ||
Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias | Q40619598 | ||
C-reactive protein and lesion morphology in patients with acute myocardial infarction | Q44497548 | ||
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial | Q44574635 | ||
Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction | Q44752428 | ||
Effect of glucose-insulin-potassium infusion on plasma free fatty acid concentrations in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction | Q45148891 | ||
Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention | Q45152229 | ||
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial | Q45238837 | ||
Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK. | Q46973471 | ||
C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | Q47191457 | ||
Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy | Q47391014 | ||
Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. | Q51095098 | ||
Role of Inflammation in Atherosclerosis | Q58492168 | ||
Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction | Q67816268 | ||
Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment | Q71703487 | ||
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year | Q72351090 | ||
C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction | Q73606387 | ||
Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial | Q77592639 | ||
Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value | Q78105403 | ||
Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report | Q79421557 | ||
Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging | Q81406260 | ||
Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein | Q82725159 | ||
Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II | Q83186798 | ||
P921 | main subject | acute coronary syndrome | Q266018 |
P304 | page(s) | 163 | |
P577 | publication date | 2015-12-03 | |
P1433 | published in | BMC Cardiovascular Disorders | Q15753126 |
P1476 | title | C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes | |
P478 | volume | 15 |
Search more.